- Mission [1]
- FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science
and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities
to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency
preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical
products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence
and accountability. The Advisory Committee for Pharmaceutical Science and Clinical Pharmacology supports FDA's strategic priorities
by reviewing and evaluating data on scientific and technical issues concerning the safety, and effectiveness of human generic
drug products for use in the treatment of a broad spectrum of human diseases, and as required, any other product for which
the Food and Drug Administration has regulatory responsibility, and make appropriate recommendations to the Commissioner of
Food and Drugs. The Committee may also review Agency sponsored intramural and extramural biomedical research programs in support
of FDA's generic drug regulatory responsibilities. This supports the development of safe and effective new medical technologies,
and advances the status of the Agency as a science-based and science-led regulatory agency, providing global leadership in
the protection of public health.
|
